Apeloa Pharmaceutical Co., Ltd.

The company was founded in 1989. It is a pharmaceutical industry development platform for the famous private enterprise Hengdian Group, and a company listed on the main board of the Shenzhen Stock Exchange. The company's API business has accumulated a large number of technical achievements and human resources, and has taken the lead and continues to invest heavily in environmental protection management, technological transformation, and product development in the Chinese API industry. It has formed a strong competitive advantage in terms of cost, quality, EHS and technology, and has become a leading domestic specialty ingredient enterprise. The main business covers R&D, production and sales of API intermediates, innovative drug R&D and production services (CDMO), formulations, etc., as well as import and export trade business. The main products include levetiracetam tablets, ufenmex capsules, cefixime series, amoxicillin and clavulanate potassium capsules, levofloxacin tablets, metoprolol succinate sustained-release tablets, fucloxacillin sodium for injection, and ceftazidime for injections (cooperation). Ranked 38th in the “2022 China Pharmaceutical Industry Top 100 Enterprises”. It was awarded the National Development and Reform Commission's “Advanced Manufacturing and Modern Service Industry Integrated Development Pilot Project” and the honorary title of “Green Factory” at the national level; won the “China Top 100 High-Growth Enterprise Award”; selected as an “Eagle Action” nurturing enterprise in Zhejiang Province; “2023 Top 20 Chinese Pharmaceutical CDMO Companies”, “2023 Industry Benchmarking Award Best Industrial Enterprise and Best Pharmaceutical Industry”, “20th place in the 2022 China Chemical Pharmaceutical Enterprise Top 100 List and 12th Chinese CXO Enterprise TOP20”; and won the “2023 National Intellectual Property Demonstration Enterprise” Many honors include “2023 National Excellent Case of Enterprise Integrity Construction Practice”, “Zhejiang Science and Technology Little Giant Enterprise”, and “Second Batch of Zhejiang Intellectual Property Demonstration Enterprises”.